. 2020 Aug 6;19:120. doi: 10.1186/s12943-020-01238-x

Table 2.

Infiltration of NK cells in different cancer types and its influence on clinical outcome

Cancer type	Sample	Detection method	Marker	Clinical outcome	Ref.
Pancreatic cancer	Blood	Flow cytometry	CD3⁻CD16⁺CD56⁺	Adverse OS	[112]
Colorectal cancer	Tumor	IHC	CD57⁺	Favorable OF and DFS	[113]
	Lymph node	IHC	CD56⁺	Favorable RFS	[114]
	Blood	Flow cytometry	CD3⁻CD16⁺CD56⁺	Favorable OS	[115]
Chronic myeloid leukemia	Blood	Flow cytometry	CD3⁻CD16⁺CD56^dim	Favorable molecular RFS after imatinib discontinuation	[116]
Chronic lymphocytic leukemia	Blood	Flow cytometry	CD3⁻CD16⁺ and/or CD56⁺	Favorable OS	[117]
Follicular lymphoma	Blood	Flow cytometry	CD3⁻CD56⁺ and/or CD16⁺	Favorable OS	[118]
Mantle cell lymphoma	Blood	Flow cytometry	CD3⁻CD16⁺ and/or CD56⁺	Adverse OS and PFS	[119]
Liver cancer	Tumor	IF	CD56⁺PD1⁺	Adverse survival	[120]
	Tumor	IHC	NKG2A⁺	Adverse OS and DFS	[46]
	Tumor	Flow cytometry	CD3⁻CD56⁺CD49a⁺	Adverse OS and DFS	[121]
	Tumor	Flow cytometry	CD3⁻CD56⁺CD96⁺	Adverse DFS	[56]
Prostate cancer	Blood	Flow cytometry	CD3⁻CD56⁺ NKp30⁺ or NKp46⁺	Favorable OS	[122]
Lung cancer	Blood	Flow cytometry	CD56^dimCD16⁺NKp46⁺	Favorable OS	[123]
	Blood	qRT-PCR	NKp30	Adverse OS and PFS	[124]
	Tumor	IF	CD56⁺ and/or CD16⁺	Favorable OS	[125]
Breast cancer	Tumor	IHC	CD3⁻CD56⁺	Favorable DFS	[126]
Breast cancer	Tumor	IHC	CD56⁺	Adverse OS	[127]
Gastric cancer	Tumor	IHC	NKG2D⁺	Favorable OS	[128]
Bladder cancer	Tumor	Flow cytometry	CD45⁺CD14⁻CD19⁻CD3⁻ILT3⁻cKIT⁻CD56^bright	Favorable OS and CSS	[129]

Abbreviations: IHC immunohistochemistry, IF immunofluorescence, qRT-PCR quantitative real time polymerase chain reaction, OS overall survival, RFS recurrence-free survival, PFS progression-free survival, DFS disease-free survival, CSS cancer-specific survival